Skip to main content

Need Immediate Care?

Find Urgent Care Locations

Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Patients with ER+/HER2− Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy

Short Title: GO46747


Enrollment Status: Recruiting

NCT #: NCT07541079

Specialty Area: Oncology

Condition Studied: Estrogen Receptor-Positive (ER+), HER2-Negative (HER2−) Early Breast Cancer

Age Groups: Adult; Older Adult

Phase: III


Study Information

Summary / Purpose

The purpose of this study is to determine whether switching to giredestrant provides a tolerable treatment option for patients with ER-positive, HER2-negative early breast cancer who are unable to tolerate aromatase inhibitor therapy while assessing patient-reported symptoms, quality of life, and treatment discontinuation.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adult females 18+ years of age
  • Must be postmenopausal
  • Confirmed ER-positive, HER2-negative early breast cancer (Stage I–III)
  • Must have an ECOG performance status of 0–1
  • Must have received aromatase inhibitor therapy for at least 6 months, including the 3 months immediately before enrollment, and experienced moderate to severe side effects
  • Must have completed prior surgery and other required treatments
  • No prior SERD therapy
  • No significant cardiac or liver disease and certain inflammatory conditions

What's Involved

Participation in the study will include:
  • Receiving the oral medication, giredestrant, once daily
  • Attending regular clinic visits
  • Blood samples collection, electrocardiograms (ECGs) and safety assessments to monitor side effects, treatment adherence, and disease status
  • Completing questionnaires about symptoms and quality of life

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.